According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic ...
An expert discusses how CheckMate 274 is a phase 3, randomized, double-blind trial evaluating adjuvant nivolumab vs placebo in patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after ...
Natural products industry companies share overviews on the latest science on their branded ingredients and formulations to ...
Galcanezumab provided greater reductions in migraine frequency, resulting in a shift from chronic to episodic migraine over a 12-month period compared with placebo.
By blocking dopamine-1 receptors, ecopipam is expected to reduce the repetitive and compulsive behaviors seen in Tourette syndrome.
Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback